Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER, about his thoughts on the future of cell and gene therapies.

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...